{
    "2018-11-29": [
        [
            {
                "time": "2018-12-01",
                "original_text": "Merck (MRK) Receives Approval for 2 HIV Medicines in EU",
                "features": {
                    "keywords": [
                        "Merck",
                        "Approval",
                        "HIV Medicines",
                        "EU"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-12-01",
                "original_text": "iShares Edge MSCI Min Vol Global ETF Experiences Big Inflow",
                "features": {
                    "keywords": [
                        "iShares",
                        "Edge MSCI",
                        "Min Vol Global ETF",
                        "Big Inflow"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "ETFs"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-12-01",
                "original_text": "Alkermes touts 'positive' schizophrenia drug data, but investors not impressed",
                "features": {
                    "keywords": [
                        "Alkermes",
                        "schizophrenia drug",
                        "positive",
                        "investors",
                        "not impressed"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-12-01",
                "original_text": "Alkermes shares dip despite 'positive' trial results from schizophrenia drug",
                "features": {
                    "keywords": [
                        "Alkermes",
                        "shares dip",
                        "positive",
                        "trial results",
                        "schizophrenia drug"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-12-01",
                "original_text": "4 Big Pharma Stocks to Add to Your Portfolio in December",
                "features": {
                    "keywords": [
                        "Big Pharma Stocks",
                        "Portfolio",
                        "December"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-12-01",
                "original_text": "Lilly to Present Clinical Data for VerzenioÂ® (abemaciclib) and Real-World Evidence across HR+, HER2- Metastatic Breast Cancer at 2018 SABCS",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Clinical Data",
                        "Verzenio",
                        "HR+",
                        "HER2-",
                        "Metastatic Breast Cancer",
                        "SABCS"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}